GeneQuine Biotherapeutics has chosen Exothera to advance the development of its osteoarthritis gene therapy product candidate, GQ-303.
GeneQuine Biotherapeutics, a biotech company focused on gene therapy for musculoskeletal disorders, has chosen Exothera, a contract development and manufacturing organization (CDMO), to advance the development of GQ-303—an osteoarthritis gene therapy product candidate.
According to a Sep. 9, 2021 press release, the partnership will see Exothera perform a feasibility study for the development of a large-scale manufacturing process for GQ-303 in GeneQuine’s highly scalable scale-X fixed-bed bioreactor. GQ-303 is an intraarticular gene therapy candidate that turns joint cells into factories for production of the therapeutic protein proteoglycan 4, which improves lubrication and inhibits molecular pathways that promote disease progression in osteoarthritis.
“New approaches in bioprocessing will be required to overcome the complexities of gene therapy manufacturing. The right process design and development is a critical early step to create a sustainable gene therapy,” said Romain de Rauville, VP Business Development at Exothera, in the press release. “We aim to provide our partners with a commercial competitive advantage and help make their innovative treatment affordable for more patients.”
“GeneQuine’s aim is to develop gene therapies for large indications. Therefore, it is crucial for us to develop a truly scalable manufacturing process to be able to serve large patient populations with GQ-303 and our other product candidates,” added Gauthier Poncelet, manufacturing manager at GeneQuine, in the press release. “We are excited to work with Exothera and leverage their expertise to evaluate the suitability of the scale X bioreactor in our production process.”
Source: GeneQuine
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.